Case Series of 23 Patients Who Developed Fatal Radiation Pneumonitis After Stereotactic Body Radiotherapy for Lung Cancer
Open Access
- 1 January 2018
- journal article
- research article
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 17
Abstract
The purpose of this study was to examine the characteristics and treatment plans of patients who experienced fatal radiation pneumonitis after stereotactic body radiation therapy for primary or oligometastatic lung cancer. Records of 1789 patients treated with stereotactic body radiation therapy for primary or oligometastatic lung cancer were retrospectively reviewed to identify those who developed fatal radiation pneumonitis. Twenty-three (1.3%; 18 men and 5 women) patients developed fatal radiation pneumonitis after stereotactic body radiation therapy for lung cancer; their median age was 74 years. The mean Krebs von den Lungen-6 level and percent vital capacity were 1320 U/mL and 82%, respectively. Prestereotactic body radiation therapy computed tomography revealed pulmonary interstitial change in 14 (73.7%) of 19 patients in whom computed tomography data could be reviewed. Seven (30.4%) of 23 patients had regularly used steroids. The median time duration between stereotactic body radiation therapy commencement and pneumonia symptom appearance was 75 (range: 14-204) days. Median survival time following pneumonia symptom appearance was 53 (range: 4-802) days. The 6- and 12-month overall survival rates were 34.8% and 13.0%, respectively. The 6-month overall survival rates in patients with and without heart disease were 50.0%, 16.7%, and 46.7% for heart disease existence, respectively. There were 4 patients in whom fatal radiation pneumonitis occurred within 2 months after stereotactic body radiation therapy and who died within 1 month. Three of them had no pulmonary interstitial change before stereotactic body radiation therapy, but had heart disease. In summary, the survival time in this case series was generally short but varied widely. More than half of the patients had pulmonary interstitial change before stereotactic body radiation therapy, although immediately progressive fatal radiation pneumonitis was also observed in patients without pulmonary interstitial change. True risk factors for fatal radiation pneumonitis should be examined in a prospective study with a larger cohort.Keywords
Funding Information
- Japan Society for the Promotion of Science (JP16H05389)
This publication has 19 references indexed in Scilit:
- Polymorphisms of the vascular endothelial growth factor gene and severe radiation pneumonitis in non‐small cell lung cancer patients treated with definitive radiotherapyCancer Science, 2012
- Early Graphical Appearance of Radiation Pneumonitis Correlates With the Severity of Radiation Pneumonitis After Stereotactic Body Radiotherapy (SBRT) in Patients With Lung TumorsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Survey of Stereotactic Body Radiation Therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy GroupInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Single Nucleotide Polymorphism at rs1982073:T869C of the TGFβ1 Gene Is Associated With the Risk of Radiation Pneumonitis in Patients With Non–Small-Cell Lung Cancer Treated With Definitive RadiotherapyJournal of Clinical Oncology, 2009
- Acute exacerbation of subclinical idiopathic pulmonary fibrosis triggered by hypofractionated stereotactic body radiotherapy in a patient with primary lung cancer and slightly focal honeycombingRadiation Medicine, 2008
- Exceptionally high incidence of symptomatic grade 2–5 radiation pneumonitis after stereotactic radiation therapy for lung tumorsRadiation Oncology, 2007
- Acute Exacerbations of Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung CancerJournal of Clinical Oncology, 2006
- Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parametersInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995